UPDATED: Cabozantinib flops against prostate cancer, forcing big job cuts at Exelixis

September 2, 2014 1:11 PM

12 0

Late on Monday evening Exelixis put out the word that its crucial late-stage study of cabozantinib flunked a comparison study with prednisone for castration-resistant prostate cancer, triggering a restructuring that will eliminate 70% of the jobs at the biotech.

This study was the big one for cabozantinib, but it failed to achieve a statistically significant improvement in overall survival among treatment-resistant patients. The cabo arm averaged an 11.0-month median OS rate compared to 9.8 months for prednisone. The median progression-free survival rate wa...

Read more

To category page